Background: The incidence of pediatric inflammatory bowel disease is increasing. tumor
necrosis factor alpha inhibitors medicines improved the prognosis of affected subjects …

Tumor necrosis factor alpha (TNF-α) inhibitors are increasingly administered to children and
adolescents with juvenile idiopathic arthritis (JIA) and pediatric inflammatory bowel disease …

Background: Although the biological agent ustekinumab (UST) is reported to be effective for
Crohn's disease (CD) in pediatric as well as adult patients, data on the efficacy and safety of …

The incidence of inflammatory bowel diseases (IBD) is increasing across the globe (1),
especially in children (2). This highlights not only the clinical importance of characterizing …

The rates of SI in JIA patients treated with infliximab ranged from 0.007 to 0.081 per patient-
year (Table 1). 10, 15, 16 Pneumonia was the most common SI in both an RCT including …

DISCUSSION Anti-TNF-a biological medications represent a tremendous advancement in
the treatment repertoire for pediatric Crohn disease. As demonstrated by this case, its use …

Ustekinumab is not recommended for the treatment of children with inflammatory bowel
disease, but its off-label use is increasing despite a lack of pediatric pharmacokinetic data …

DISCUSSION TNF-a inhibitors are the only biological agents approved for pediatric CD
treatment. A substantial proportion of patients, however, either are primary nonresponders or …

A 17-year-old immunocompetent female presented with symptoms of extreme fatigue,
headache, dizziness, weight loss of 6 kg, and arthralgia in her wrist and knee joints. She had …

Background: Ustekinumab is an effective therapy for Crohn disease currently approved for
adults. Off-label use in the pediatric population is increasing, but its effectiveness in this age …